SOPH · SOPHiA GENETICS SA

Current Thesis

SOPHiA GENETICS' cloud-genomics expansion thesis depends on renewed price strength above the market's $8.92 high and a further revenue-guidance increase at the next quarterly report. The operating foundation remains the 2026-08-04 results: net dollar retention of 117%, compared with 107% a year earlier, and FY2026 revenue guidance raised to $94–96 million. The AstraZeneca collaboration announced that day covers two companion-diagnostic programs; it establishes a named commercial relationship, but does not by itself establish future revenue.

The September refresh shows consolidation rather than a confirmed new advance. The supplied adjusted market series closed at $8.19 on 2026-09-18, compared with $8.09 on 2026-09-04, while the 14-day relative strength index (RSI) eased to 50.8 from 56.8. As an inference from those observations, the narrative is maturing — August's operating improvement remains the anchor, while the September price observations do not establish accelerating participation. A weekly close above the $8.92 high would challenge that classification; a weekly close below $6.84 would invalidate the price thesis.

Bullish and bearish views on SOPHiA GENETICS SA

The model's bull view on SOPHiA GENETICS SA (SOPH), in brief: Existing customers expanded their spending. The bear view: Margins weakened despite higher activity. Both cases follow in full.

Bull Case

• Existing customers expanded their spending. The company's 2026-08-04 results reported Q2 net dollar retention of 117%, versus 107% a year earlier. That supports the expansion thesis within the installed customer base; durability remains unproven beyond the reported quarter.
• Activity and customer counts increased. The 2026-08-04 release reported 542 core genomics customers versus 490 a year earlier, alongside 115,000 quarterly analyses, up 22% year over year. These are operating measures supporting the platform narrative.
• Revenue supported a higher outlook. Q2 2026 revenue was $23.310 million, up 27% reported and 25% in constant currency, according to the 2026-08-04 release. Management increased FY2026 revenue guidance to $94–96 million from $92–94 million.
• Pharma collaboration has defined programs. The 2026-08-04 AstraZeneca announcement identified a decentralized solid-tumour companion diagnostic and a hematological oncology test. The supplied announcement contains no contract-value figure, so its revenue contribution cannot be quantified here.

Bear Case

• Margins weakened despite higher activity. The 2026-08-04 results reported Q2 adjusted gross margin of 72.1%, versus 74.4% a year earlier, citing cloud costs, services mix and project ramps. Another quarter at or below 72.1% would undermine the operating-leverage interpretation.
• Losses remain material against revenue. The same 2026-08-04 release reported a Q2 net loss of $22.4 million and an adjusted loss before interest, taxes, depreciation and amortization of $8.8 million. The adjusted measure does not establish cash consumption or profitability.
• Equity funding expanded the share supply. The company's 2026-06-19 closing announcement reported $57.5 million in gross offering proceeds, including full exercise of the underwriters' option. This is documented financing, not evidence of subsequent market selling. Company offering announcement.
• Lock-up expiry is newly relevant. MarketScreener reported on 2026-09-14 that restrictions on certain options and restricted share units ended on 2026-09-15. Expiry alone establishes neither exercise nor disposal. Dated lock-up report.

Setup & Price Structure

The 2026-09-18 adjusted reference close of $8.19 was 8.2% below the supplied 52-week high of $8.92, after a three-month price increase of 53.4%. The market's 2026-08-21 close of $8.65 remains an intermediate reference, while the 2026-08-04 post-results close of $6.84 remains the thesis-break level. A weekly close above $8.92 would satisfy the price component of the continuation case; the observations supplied do not establish that breakout.

Public attention is observable, but crowding is not established. Zacks published a momentum article on 2026-09-18 that attributed renewed interest to the previously reported Q2 performance. That attribution is Zacks' interpretation, and one article cannot establish retail-sentiment clustering. Zacks coverage.

The company's filing index lists Form 4 reports dated 2026-08-31, so a blanket assertion that no insider-reporting record exists is unsupported. The index alone does not establish transaction direction, motivation or aggregate insider selling. No moving-average value or short-interest measure is supplied for 2026-09-18. Company filing index.

Catalyst Calendar (next 30 days)

• 2026-09-22 to 2026-09-23 — Americas Innovation Summit. The company calendar lists the Nashville event for clinicians, researchers and biopharma participants. Its scheduled occurrence does not establish a financial disclosure; an announcement would need explicit commercial terms to change the revenue assessment. Company event calendar.
• 2026-10-05 to 2026-10-08 — World CB & CDx Boston. The company calendar identifies this clinical-biomarker and companion-diagnostics event. It is relevant to the programs announced with AstraZeneca on 2026-08-04, but attendance itself does not confirm monetization. Company event calendar.
• ~2026-11-03, estimated — Q3 2026 results. This later event is the operating test of the thesis. MarketBeat explicitly labels the date estimated; company confirmation is missing. The report would establish whether retention sustains August's improvement and whether the $94–96 million FY2026 revenue range rises again. Estimated earnings calendar.

What Would Change Our Mind

Loss of the August results reference would break the price structure: a weekly close below $6.84, the 2026-08-04 post-results close, ends the continuation thesis. This is an analytical condition tied to the public adjusted price series.

The operating case requires a second improvement in expectations. At the Q3 report estimated for 2026-11-03, an unchanged or lower $94–96 million FY2026 revenue range would fail that test; net dollar retention below 110% would separately contradict sustained customer expansion. These are prospective research conditions, not company guidance. Retention at least matching Q2's 117%, a higher annual revenue range and adjusted gross margin above Q2's 72.1% would provide the operating confirmation presently missing.

Correlation Notes

This remains a single-company setup in the 2026-09-20 assessment: no active peer cluster or paired return series is supplied. The evidence is insufficient to claim a measured correlation with artificial-intelligence software or diagnostics shares. The relevant company-specific exposures are the genomics activity and AstraZeneca programs disclosed on 2026-08-04.

Currency is a documented reporting exposure. Q2 2026 revenue growth was 27% reported versus 25% in constant currency in the 2026-08-04 release. That difference does not establish an equity-price correlation with the dollar, and no such coefficient is available.